Fintel reports that on January 10, 2025, Piper Sandler upgraded their outlook for NIKE (NYSE:NKE) from Neutral to Overweight.
Michael Kantrowitz, Piper Sandler chief investment strategist, joins 'The Exchange' to discuss why higher rates pose the ...
ET, Dow E-minis were down 66 points, or 0.15%, S&P 500 E-minis were lower 18.25 points, or 0.31% and Nasdaq 100 E-minis were off 78.75 points, or 0.37% ...
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) today and set a price target of ...
Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...